"The ongoing challenges to its generics business and that with FDA approval of Mylan's generic of Copaxone, earnings/cash flow are likely to affected," Jefferies analyst David Steinberg wrote in a note. "[Although Copaxone] has been a strong contributor to cash flow over the last two decades, growing generic competition to this franchise has been an overhang on TEVA shares in recent years."